Hims & Hers Health (NYSE:HIMS) PT Raised to $16.00

Hims & Hers Health (NYSE:HIMS) had its price target upped by equities research analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 31.58% from the company’s current price.

Several other equities analysts have also commented on the company. TheStreet raised Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Jefferies Financial Group reiterated a “hold” rating and issued a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. SVB Leerink assumed coverage on Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 price target on the stock. Guggenheim increased their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Piper Sandler lifted their target price on Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average price target of $15.07.

Hims & Hers Health Stock Down 1.5 %

NYSE:HIMS opened at $12.16 on Tuesday. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $17.16. The company has a market cap of $2.61 billion, a PE ratio of -107.91 and a beta of 0.97. The business’s 50 day moving average is $14.01 and its two-hundred day moving average is $10.39.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The firm’s revenue was up 45.8% on a year-over-year basis. As a group, sell-side analysts expect that Hims & Hers Health will post 0.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Andrew Dudum sold 50,361 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total transaction of $822,898.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $15.65, for a total value of $39,171.95. Following the sale, the insider now owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 736,191 shares of company stock worth $9,733,700. 31.63% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Forerunner Ventures Management LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth $86,836,000. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after buying an additional 428,671 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Hims & Hers Health by 39.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock worth $8,006,000 after buying an additional 357,590 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Hims & Hers Health by 38.6% during the 3rd quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock worth $6,494,000 after acquiring an additional 287,552 shares in the last quarter. Finally, Must Asset Management Inc. acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $1,596,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.